BLOOD 2021

Congratulations to all investigators who contributed and presented the following accepted presentation and abstracts at BLOOD 2021.

• Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR)
• Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry
• Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
• Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry
• Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience
• Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR)

Thank you for supporting our colleagues virtually at BLOOD. See you again next year!

Read more: https://lardr.org/research/#Researchpublications